These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9777981)

  • 1. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases.
    Vergier B; Beylot-Barry M; Pulford K; Michel P; Bosq J; de Muret A; Beylot C; Delaunay MM; Avril MF; Dalac S; Bodemer C; Joly P; Groppi A; de Mascarel A; Bagot M; Mason DY; Wechsler J; Merlio JP
    Am J Surg Pathol; 1998 Oct; 22(10):1192-202. PubMed ID: 9777981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations.
    Beylot-Barry M; Groppi A; Vergier B; Pulford K; Merlio JP
    Blood; 1998 Jun; 91(12):4668-76. PubMed ID: 9616164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.
    Su LD; Schnitzer B; Ross CW; Vasef M; Mori S; Shiota M; Mason DY; Pulford K; Headington JT; Singleton TP
    J Cutan Pathol; 1997 Nov; 24(10):597-603. PubMed ID: 9449486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
    Benner MF; Jansen PM; Meijer CJ; Willemze R
    Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
    Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
    Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
    Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas.
    van Haselen CW; Vermeer MH; Toonstra J; van der Putte SC; Mulder PG; van Vloten WA; Willemze R
    J Cutan Pathol; 1997 Sep; 24(8):462-7. PubMed ID: 9331891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal Involvement by CD30
    Lezama LS; Gratzinger D
    Arch Pathol Lab Med; 2018 Jan; 142(1):139-142. PubMed ID: 29257929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients.
    Beljaards RC; Kaudewitz P; Berti E; Gianotti R; Neumann C; Rosso R; Paulli M; Meijer CJ; Willemze R
    Cancer; 1993 Mar; 71(6):2097-104. PubMed ID: 8382999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of carbohydrate antigens, p80NPM/ALK, cytotoxic cell-associated antigens, and Epstein-Barr virus gene products in anaplastic large cell lymphomas.
    Kasai K; Kon S; Kikuchi K; Sato Y; Kameya T
    Pathol Int; 1998 Mar; 48(3):171-8. PubMed ID: 9589484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
    Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
    J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the t(2;5) (p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
    Wood GS
    Leuk Lymphoma; 1998 Mar; 29(1-2):93-101. PubMed ID: 9638979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
    Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
    Beylot-Barry M; Lamant L; Vergier B; de Muret A; Fraitag S; Delord B; Dubus P; Vaillant L; Delaunay M; MacGrogan G; Beylot C; de Mascarel A; Delsol G; Merlio JP
    Am J Pathol; 1996 Aug; 149(2):483-92. PubMed ID: 8701987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.
    Kapur S; Tiemann M; Menke MA; Schubert C; Parwaresch R
    Indian J Med Res; 2005 Jan; 121(1):46-54. PubMed ID: 15713979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.
    Paulli M; Berti E; Boveri E; Kindl S; Bonoldi E; Gambini C; Rosso R; Borroni G; Straccapansa V; Magrini U; DeCoteau JE; Krammer PH; Möller P; Kadin ME
    Hum Pathol; 1998 Nov; 29(11):1223-30. PubMed ID: 9824099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
    Geissinger E; Sadler P; Roth S; Grieb T; Puppe B; Müller N; Reimer P; Vetter-Kauczok CS; Wenzel J; Bonzheim I; Rüdiger T; Müller-Hermelink HK; Rosenwald A
    Haematologica; 2010 Oct; 95(10):1697-704. PubMed ID: 20511667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
    Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
    Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases.
    Macgrogan G; Vergier B; Dubus P; Beylot-Barry M; Belleannee G; Delaunay MM; Eghbali H; Beylot C; Rivel J; Trojani M; Vital C; De Mascarel A; Bloch B; Merlio JP
    Am J Clin Pathol; 1996 Apr; 105(4):440-50. PubMed ID: 8604686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The t(2;5) in human lymphomas.
    Kadin ME; Morris SW
    Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.